NEW UK VARIANT AND EVALUATION OF ANTIBODY ESCAPE

Study code
NBR118

Lead researcher
Ravi Gupta

Study type
Samples and data

Institution or company
University of Cambridge

Speciality area
Infection

Summary

With new COVID-19 variants of the virus emerging, it is more important than ever to understand if, and how, our current vaccines respond to the effects of these new variants. This will help us understand whether the new variant virus is evading antibody responses and therefore whether the current vaccines offer adequate protection against novel COVID-19 variants.

This study aims to look at these outcomes in a group of over 150 volunteers whom have received both doses of either the Oxford AstraZeneca or Pfizer-BioNTech COVID-19 vaccination. Testing has already begun and is set to continue over the course of one year, with participants being invited for a recall appointment at 3, 6 and 12 months.